Xeris Net Tangible Assets vs Non Currrent Assets Other Analysis

XERS Stock  USD 3.51  0.07  1.96%   
Xeris Pharmaceuticals financial indicator trend analysis is more than just analyzing Xeris Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Xeris Pharmaceuticals is a good investment. Please check the relationship between Xeris Pharmaceuticals Net Tangible Assets and its Non Currrent Assets Other accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.

Net Tangible Assets vs Non Currrent Assets Other

Net Tangible Assets vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Xeris Pharmaceuticals Net Tangible Assets account and Non Currrent Assets Other. At this time, the significance of the direction appears to have strong contrarian relationship.
The correlation between Xeris Pharmaceuticals' Net Tangible Assets and Non Currrent Assets Other is -0.56. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Xeris Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Xeris Pharmaceuticals' Net Tangible Assets and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Xeris Pharmaceuticals are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Net Tangible Assets i.e., Xeris Pharmaceuticals' Net Tangible Assets and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

-0.56
Relationship DirectionNegative 
Relationship StrengthVery Weak

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.
Most indicators from Xeris Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Xeris Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xeris Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Xeris Stock please use our How to Invest in Xeris Pharmaceuticals guide.Enterprise Value is likely to gain to about 509.5 M in 2024, whereas Selling General Administrative is likely to drop slightly above 79.7 M in 2024.
 2021 2022 2023 2024 (projected)
Depreciation And Amortization1.9M12.7M13.2M13.8M
Interest Income313K2.6M4.8M5.0M

Xeris Pharmaceuticals fundamental ratios Correlations

0.920.90.660.94-0.420.940.840.83-0.950.770.890.910.270.740.780.840.90.880.940.890.910.980.960.80.76
0.921.00.440.98-0.570.990.90.96-0.980.940.780.980.390.880.660.960.950.970.90.910.840.910.920.930.67
0.91.00.440.97-0.550.990.890.97-0.980.950.750.980.40.90.650.970.940.980.880.910.830.90.90.950.68
0.660.440.440.50.360.470.530.43-0.560.280.550.4-0.120.240.90.350.570.410.360.690.650.70.410.330.63
0.940.980.970.5-0.530.990.870.91-0.970.910.840.970.420.790.690.90.920.920.910.880.810.910.930.850.66
-0.42-0.57-0.550.36-0.53-0.59-0.3-0.430.45-0.51-0.54-0.65-0.56-0.650.13-0.6-0.35-0.61-0.68-0.19-0.38-0.31-0.63-0.58-0.04
0.940.990.990.470.99-0.590.870.93-0.980.910.830.990.430.870.660.950.920.970.920.890.860.910.930.920.66
0.840.90.890.530.87-0.30.870.92-0.940.860.590.810.080.730.750.830.950.840.760.950.830.910.80.830.75
0.830.960.970.430.91-0.430.930.92-0.960.960.590.910.30.890.640.960.950.940.780.930.780.870.820.950.69
-0.95-0.98-0.98-0.56-0.970.45-0.98-0.94-0.96-0.9-0.78-0.95-0.26-0.84-0.76-0.93-0.98-0.95-0.9-0.96-0.88-0.96-0.92-0.91-0.75
0.770.940.950.280.91-0.510.910.860.96-0.90.570.90.480.820.50.90.870.880.780.840.660.780.80.880.63
0.890.780.750.550.84-0.540.830.590.59-0.780.570.840.360.60.650.680.70.760.880.650.790.790.860.620.52
0.910.980.980.40.97-0.650.990.810.91-0.950.90.840.520.890.580.950.880.970.920.830.830.870.930.920.6
0.270.390.4-0.120.42-0.560.430.080.3-0.260.480.360.520.42-0.190.410.090.410.370.080.170.150.360.380.04
0.740.880.90.240.79-0.650.870.730.89-0.840.820.60.890.420.430.980.80.960.760.750.770.730.780.990.53
0.780.660.650.90.690.130.660.750.64-0.760.50.650.58-0.190.430.560.810.60.550.870.750.830.590.530.77
0.840.960.970.350.9-0.60.950.830.96-0.930.90.680.950.410.980.560.890.990.830.850.810.830.850.990.63
0.90.950.940.570.92-0.350.920.950.95-0.980.870.70.880.090.80.810.890.90.820.980.830.940.850.880.74
0.880.970.980.410.92-0.610.970.840.94-0.950.880.760.970.410.960.60.990.90.870.860.870.870.890.980.63
0.940.90.880.360.91-0.680.920.760.78-0.90.780.880.920.370.760.550.830.820.870.750.830.881.00.790.64
0.890.910.910.690.88-0.190.890.950.93-0.960.840.650.830.080.750.870.850.980.860.750.850.950.80.840.82
0.910.840.830.650.81-0.380.860.830.78-0.880.660.790.830.170.770.750.810.830.870.830.850.930.850.810.72
0.980.910.90.70.91-0.310.910.910.87-0.960.780.790.870.150.730.830.830.940.870.880.950.930.920.810.81
0.960.920.90.410.93-0.630.930.80.82-0.920.80.860.930.360.780.590.850.850.891.00.80.850.920.820.68
0.80.930.950.330.85-0.580.920.830.95-0.910.880.620.920.380.990.530.990.880.980.790.840.810.810.820.61
0.760.670.680.630.66-0.040.660.750.69-0.750.630.520.60.040.530.770.630.740.630.640.820.720.810.680.61
Click cells to compare fundamentals

Xeris Pharmaceuticals Account Relationship Matchups

Xeris Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets120.0M109.0M159.2M344.5M322.6M203.3M
Other Current Liab21.7M25.1M70.1M65.9M80.1M84.1M
Total Current Liabilities10.2M27.3M28.2M73.6M95.2M100.0M
Total Stockholder Equity75.4M14.4M33.8M45.2M(6.8M)(6.4M)
Other Liab8.9M10.2M42.0M29.2M33.6M35.3M
Net Tangible Assets14.4M33.8M(59.1M)(98.3M)(88.5M)(84.0M)
Property Plant And Equipment Net2.0M7.9M6.7M28.4M29.2M30.6M
Net Debt(13.8M)38.8M49.4M76.1M161.7M169.8M
Retained Earnings(120.7M)(246.2M)(337.4M)(554.8M)(617.0M)(586.2M)
Accounts Payable5.6M3.1M8.9M4.6M11.6M12.1M
Cash45.7M19.5M37.6M122.0M67.4M67.2M
Non Current Assets Total2.1M21.5M6.9M157.7M166.3M174.7M
Non Currrent Assets Other420K(13.0M)4.7M267K4.5M4.8M
Other Assets420K232K829K4.7M5.4M5.7M
Cash And Short Term Investments112.6M75.5M133.8M122.0M72.5M98.0M
Net Receivables5.6M6.9M17.5M30.8M39.2M41.2M
Liabilities And Stockholders Equity120.0M109.0M159.2M344.5M322.6M203.3M
Non Current Liabilities Total34.5M67.2M97.2M225.7M234.2M143.7M
Capital Surpluse2.8M196.1M260.6M371.1M426.8M448.1M
Other Current Assets4.1M3.2M4.6M9.3M5.8M4.3M
Other Stockholder Equity260.6M371.1M555.4M600.0M610.3M357.4M
Total Liab44.6M94.6M125.4M299.3M329.4M187.1M
Property Plant And Equipment Gross7.9M6.7M10.8M28.4M35.2M37.0M
Total Current Assets117.9M87.5M152.2M186.8M156.3M132.6M
Accumulated Other Comprehensive Income(52K)43K6K(23K)(25K)(26.3K)
Short Term Debt2.6M8.2M1.6M3.2M3.5M3.6M
Common Stock2K3K6K14K16.1K16.9K
Property Plant Equipment7.9M6.7M6.6M9.5M10.9M11.5M
Net Invested Capital72.7M120.8M183.3M232.3M184.2M132.4M
Net Working Capital60.1M124.0M63.6M113.2M61.1M89.4M
Long Term Debt58.3M87.0M88.1M187.1M190.9M117.9M
Short Term Investments56.0M96.2M35.2M0.05.0M4.8M
Capital Stock3K6K13K14K16.1K9.5K
Non Current Liabilities Other8.9M3.5M30.2M25.7M6.2M5.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Xeris Stock Analysis

When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.